AIDS and Behavior

, Volume 18, Supplement 3, pp 340–347 | Cite as

Knowledge of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men in Denver, Colorado

  • Alia A. Al-Tayyib
  • Mark W. Thrun
  • Jason S. Haukoos
  • N. Eugene Walls
Original Paper


As part of the National HIV Behavioral Surveillance System among men who have sex with men (MSM) in Denver, Colorado, we assessed knowledge of pre-exposure prophylaxis (PrEP); willingness to use PrEP; and potential changes in risk behaviors among HIV-negative participants reporting sexual activity with a male partner in the preceding 12 months. We examined knowledge of PrEP before (2008) and after (2011) results of the iPrEx trial were available. Of the 425 participants in the 2008 sample, 91 (21 %) were aware of PrEP compared to 131 (28 %) of the 461 participants in the 2011 sample (adjusted prevalence ratio: 1.43, 95 % confidence interval: 1.18, 1.72). Despite the increase in 2011, few MSM in Denver were aware of PrEP. Educating high-risk MSM about the potential utility of PrEP as an adjunct to other effective prevention methods is needed when considering the addition of PrEP to the HIV prevention arsenal.


Behavioral surveillance  Men who have sex with men  Pre-exposure prophylaxis 



This work was supported in part by the Centers for Disease Control and Prevention (U62-PS000954). Data collection was based on CDC study protocols as part of the National HIV Behavioral Surveillance System. The authors gratefully acknowledge the contributions of Drs. Dawn Smith, Andrew Voetsch, Jeffrey Herbst, and James Carey to the PrEP questionnaire and to earlier presentations of this data. The authors are deeply indebted to Drs. Elizabeth DiNenno and Nevin Krishna for continued NHBS support during the development of this manuscript. The authors also thank Toby LeRoux, Charles Chen, Theresa Mickiewicz, and our Denver NHBS interviewers for their tireless efforts in collecting this important data and to the numerous NHBS participants who provided it.


  1. 1.
    Cohen MS, Holmes C, Padian N, Wolf M, Hirnschall G, Lo YR, et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff (Millwood). 2012;31(7):1439–49.CrossRefGoogle Scholar
  2. 2.
    Flash C, Krakower D, Mayer KH. The promise of antiretrovirals for HIV prevention. Curr Infect Dis Rep. 2012;14(2):185–93.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Person AK, Hicks CB. Pre-exposure prophylaxis—one more tool for HIV prevention. Curr HIV Res. 2012;10(2):117–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2012;379(9835):2409–11.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Abdool Karim SS. Top stories of 2008. The prospect of PrEP. AIDS Clin Care. 2009;21(1):6.PubMedGoogle Scholar
  6. 6.
    Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146(8):591–601.PubMedCrossRefGoogle Scholar
  7. 7.
    Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic). 2003;2(3):102–5.CrossRefGoogle Scholar
  8. 8.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    U.S. Food and Drug Administration. FDA approves first drug for reducing risk of sexually acquired HIV infection. 2012 [cited 30 Oct 2012]. Available from:
  12. 12.
    CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(03):65–8.Google Scholar
  13. 13.
    CDC. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61(31):586–9.Google Scholar
  14. 14.
    CDC. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep. 2013;62(23):463–5.Google Scholar
  15. 15.
    Fisher M. Preexposure prophylaxis for HIV infection: it’s not as easy as ABC. Curr Opin Infect Dis. 2007;20(1):1–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Buchbinder SP, Liu A. Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav. 2011;15(Suppl 1):S72–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, Matheson T, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47(2):241–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Voetsch AC, Heffelfinger JD, Begley EB, Jafa-Bhushan K, Sullivan PS. Knowledge and use of preexposure and postexposure prophylaxis among attendees of Minority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr. 2007;46(3):378–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, Sullivan P. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr. 2006;43(3):376–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Mansergh G, Koblin BA, Colfax GN, McKirnan DJ, Flores SA, Hudson SM. Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among US men who have sex with men. J Acquir Immune Defic Syndr. 2010;55(2):e14–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the U.S.: the National HIV Behavioral Surveillance System. Public Health Rep. 2007;122(Suppl 1):32–8.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Karon J. The analysis of time-location sampling data. American Statistical Association Section of Survey Research Methods 2005, Minneapolis; 2005. p. 3180–3186.Google Scholar
  25. 25.
    Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7(3):e33119.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Galindo GR, Walker JJ, Hazelton P, Lane T, Steward WT, Morin SF, et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci. 2012;7:116.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Rucinski KB, Mensah NP, Sepkowitz KA, Cutler BH, Sweeney MM, Myers JE. Knowledge and use of pre-exposure prophylaxis among an online sample of young men who have sex with men in New York City. AIDS Behav. 2013;17(6):2180–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Saberi P, Gamarel KE, Neilands TB, Comfort M, Sheon N, Darbes LA, et al. Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study. PLoS One. 2012;7(11):e50061.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Underhill K, Morrow KM, Operario D, Mayer KH. Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men. AIDS Behav. 2013. doi:10.1007/s10461-013-0498-9.Google Scholar
  30. 30.
    Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS One. 2012;7(1):e28238.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Alia A. Al-Tayyib
    • 1
    • 2
  • Mark W. Thrun
    • 1
    • 3
  • Jason S. Haukoos
    • 2
    • 4
  • N. Eugene Walls
    • 5
  1. 1.Denver Public HealthDenver Health and Hospital AuthorityDenverUSA
  2. 2.Department of EpidemiologyColorado School of Public HealthAuroraUSA
  3. 3.Department of MedicineUniversity of Colorado School of MedicineAuroraUSA
  4. 4.Department of Emergency MedicineDenver Health and Hospital AuthorityDenverUSA
  5. 5.Graduate School of Social WorkUniversity of DenverDenverUSA

Personalised recommendations